Ti DD, Liu P, Wu CY, Shi ZM, Guo SM, Gao ZC. Host and gut microbiota crosstalk: A new paradigm for colorectal cancer immunotherapy. World J Clin Oncol 2026; 17(4): 118606 [DOI: 10.5306/wjco.v17.i4.118606]
Corresponding Author of This Article
Shu-Ming Guo, Clinical Medicine Research Center, Linfen Central Hospital, No. 17 Jiefang West Road, Yaodu District, Linfen 041000, Shanxi Province, China. guoshuming70@163.com
Research Domain of This Article
Immunology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Apr 24, 2026 (publication date) through Apr 22, 2026
Times Cited of This Article
Times Cited (0)
Journal Information of This Article
Publication Name
World Journal of Clinical Oncology
ISSN
2218-4333
Publisher of This Article
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Share the Article
Ti DD, Liu P, Wu CY, Shi ZM, Guo SM, Gao ZC. Host and gut microbiota crosstalk: A new paradigm for colorectal cancer immunotherapy. World J Clin Oncol 2026; 17(4): 118606 [DOI: 10.5306/wjco.v17.i4.118606]
Dong-Dong Ti, Peng Liu, Chun-Yan Wu, Zhi-Ming Shi, Shu-Ming Guo, Clinical Medicine Research Center, Linfen Central Hospital, Linfen 041000, Shanxi Province, China
Zhan-Cheng Gao, Department of Respiratory and Critical Care Medicine, Peking University People’s Hospital, Beijing 100044, China
Co-first authors: Dong-Dong Ti and Peng Liu.
Co-corresponding authors: Shu-Ming Guo and Zhan-Cheng Gao.
Author contributions: Ti DD and Liu P made equal contributions as co-first authors; Ti DD contributed to the writing of manuscript; Liu P and Wu CY were mainly involved in organizing the figures and the literatures; Shi ZM, Gao ZC, and Guo SM revised and edited this manuscript; Guo SM and Gao ZC made equal contributions as co-corresponding authors. All authors have read and approved the final version of the manuscript to be published.
Supported by National Natural Science Foundation of China, No. 31971378.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Corresponding author: Shu-Ming Guo, Clinical Medicine Research Center, Linfen Central Hospital, No. 17 Jiefang West Road, Yaodu District, Linfen 041000, Shanxi Province, China. guoshuming70@163.com
Received: January 7, 2026 Revised: January 27, 2026 Accepted: February 24, 2026 Published online: April 24, 2026 Processing time: 104 Days and 19.8 Hours
Core Tip
Core Tip: From birth onward, host health is closely linked to the delicate balance of ecological microbiota composition. The microbiota utilizes distinct enzymatic capabilities to metabolize nutrients and produce immunomodulatory byproducts that influence organ function and behavior. A strong and rapid association has been identified between gut microbiome dysbiosis, defined as a disruption in microbial load or diversity, colorectal cancer pathogenesis, and responsiveness to immunotherapy. Therefore, clarify the mechanism of gut microbiome dysbiosis and develop microbe-based intervention through health-oriented and adaptable mechanisms, such as oral probiotic administration, will become an indispensable component of colorectal cancer immunotherapy in the future.
